Anja Schneider

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2174738/publications.pdf

Version: 2024-02-01

152 papers	9,023 citations	61984 43 h-index	48315 88 g-index
170 all docs	170 docs citations	170 times ranked	12765 citing authors

#	Article	IF	Citations
1	Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers. Alzheimer's and Dementia, 2023, 19, 487-497.	0.8	25
2	Amyloid pathology but notAPOEÎµ4 status is permissive for tau-related hippocampal dysfunction. Brain, 2022, 145, 1473-1485.	7.6	17
3	The impact of COVID-19-related distress on levels of depression, anxiety and quality of life in psychogeriatric patients. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 53-66.	3.2	8
4	Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimerâ€™s disease. Neuron, 2022, 110, 1009-1022.e4.	8.1	27
5	Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimerâ€™s type. Brain, 2022, 145, 2507-2517.	7.6	16
6	Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimerâ€™s Disease Spectrum. Journal of Alzheimer's Disease, 2022, 85, 1267-1282.	2.6	12
7	Relevance of Subjective Cognitive Decline in Older Adults with a First-Degree Family History of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 87, 545-555.	2.6	5
8	New insights into the genetic etiology of Alzheimerâ€™s disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
9	Comparative analysis of machine learning algorithms for multi-syndrome classification of neurodegenerative syndromes. Alzheimer's Research and Therapy, 2022, 14, 62.	6.2	9
10	Protein lifetimes in aged brains reveal a proteostatic adaptation linking physiological aging to neurodegeneration. Science Advances, 2022, 8, .	10.3	22
11	Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	9.0	31
12	One-Stop Shop: ¹⁸F-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases. Journal of Nuclear Medicine, 2021, 62, 240-246.	5.0	18
13	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 614-628.	7.9	61
14	Abnormal Regional and Global Connectivity Measures in Subjective Cognitive Decline Depending on Cerebral Amyloid Status. Journal of Alzheimer's Disease, 2021, 79, 493-509.	2.6	14
15	Association between composite scores of domain-specific cognitive functions and regional patterns of atrophy and functional connectivity in the Alzheimerâ€™s disease spectrum. NeuroImage: Clinical, 2021, 29, 102533.	2.7	15
16	Quantifying progression in primary progressive aphasia with structural neuroimaging. Alzheimer's and Dementia, 2021, 17, 1595-1609.	0.8	22
17	Hippocampal and Hippocampal-Subfield Volumes From Early-Onset Major Depression and Bipolar Disorder to Cognitive Decline. Frontiers in Aging Neuroscience, 2021, 13, 626974.	3.4	15
18	MicroRNAs from extracellular vesicles as a signature for Parkinson's disease. Clinical and Translational Medicine, 2021, 11, e357.	4.0	14

#	Article	IF	Citations
19	<scp>Î±â€Synuclein</scp> in Plasmaâ€Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease. Movement Disorders, 2021, 36, 2508-2518.	3.9	47
20	Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age. Neurology, 2021, 96, .	1.1	72
21	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	12.8	140
22	Resting-State Network Alterations Differ between Alzheimerâ€™s Disease Atrophy Subtypes. Cerebral Cortex, 2021, 31, 4901-4915.	2.9	12
23	Motor speech disorders in the nonfluent, semantic and logopenic variants of primary progressive aphasia. Cortex, 2021, 140, 66-79.	2.4	10
24	Clinico-genetic findings in 509 frontotemporal dementia patients. Molecular Psychiatry, 2021, 26, 5824-5832.	7.9	23
25	A microRNA signature that correlates with cognition and is a target against cognitive decline. EMBO Molecular Medicine, 2021, 13, e13659.	6.9	29
26	Improving 3D convolutional neural network comprehensibility via interactive visualization of relevance maps: evaluation in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2021, 13, 191.	6.2	21
27	Predicting disease progression in behavioral variant frontotemporal dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12262.	2.4	4
28	Memorability analysis for diagnostic photographs in cognitive assessment: Linking behavioral performance with biomarker status. Alzheimer's and Dementia, 2021, 17, .	0.8	1
29	Lifelong music practice as reserve factor: Associations with cognition and brain structure in older adults. Alzheimer's and Dementia, 2021, 17, .	0.8	1
30	Factors influencing atrophy progression in primary progressive aphasia. Alzheimer's and Dementia, 2021, 17, .	0.8	0
31	Cost of illness of apathy in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
32	Characterization of the NIAâ€AA Research Framework stage 2 in the longitudinal multicenter DELCODE study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
33	In vivo amyloid staging in individuals with subjective cognitive decline in DELCODE Study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
34	Artificial neural network visualization methods reveal diagnostically relevant brain regions to detect Alzheimerâ€™s disease: The first step towards comprehensive artificial intelligence. Alzheimer's and Dementia, 2021, 17, .	0.8	0
35	Prediction of amyloidâ€positivity in individuals with subjective cognitive decline: Machine learning approaches to optimize numberâ€neededâ€toâ€screen. Alzheimer's and Dementia, 2021, 17, .	0.8	0
36	A rare heterozygous TREM2 coding variant identified in familial clustering of dementia affects an intrinsically disordered protein region and function of TREM2. Human Mutation, 2020, 41, 169-181.	2.5	4

#	Article	IF	Citations
37	Disentangling brain functional network remodeling in corticobasal syndrome â€“ A multimodal MRI study. NeuroImage: Clinical, 2020, 25, 102112.	2.7	10
38	Glucocorticoid Therapy is Associated with a Lower Risk of Dementia. Journal of Alzheimer's Disease, 2020, 73, 175-183.	2.6	10
39	Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkersâ€"results from the DELCODE study. Alzheimer's Research and Therapy, 2020, 12, 131.	6.2	17
40	Network Localization of Alien Limb in Patients with Corticobasal Syndrome. Annals of Neurology, 2020, 88, 1118-1131.	5.3	11
41	LifeTime and improving European healthcare through cell-based interceptive medicine. Nature, 2020, 587, 377-386.	27.8	108
42	Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients. Alzheimer's and Dementia, 2020, 16, 1504-1514.	0.8	35
43	Multimodal MRI analysis of basal forebrain structure and function across the Alzheimerâ€™s disease spectrum. NeuroImage: Clinical, 2020, 28, 102495.	2.7	17
44	Feasibility of mobile appâ€based assessment of memory functions: Insights from a citizen science study. Alzheimer's and Dementia, 2020, 16, e039149.	0.8	1
45	Cognitive and biological characteristics of stage 2 of AD in the clinical multicenter DELCODE Study. Alzheimer's and Dementia, 2020, 16, e040265.	0.8	0
46	Altered resting state activity associated with anosognosia in Alzheimer's clinical syndrome: Findings from the DELCODE study. Alzheimer's and Dementia, 2020, 16, e040416.	0.8	0
47	Lifestyle differences modulate the effects of cognitive reserve on functional connectivity. Alzheimer's and Dementia, 2020, 16, e042947.	0.8	0
48	Hippocampal volumetric variability is associated with memory in subjective cognitive decline. Alzheimer's and Dementia, 2020, 16, e043527.	0.8	0
49	Decreased cortical thickness in individuals with subjective cognitive decline with and without CSFâ€ADâ€pathology: Data from the DELCODE Study. Alzheimer's and Dementia, 2020, 16, e044741.	0.8	1
50	Awareness of cognitive decline and CSFâ€biomarkers in memory clinic patients: Results from the DELCODEâ€study. Alzheimer's and Dementia, 2020, 16, e044744.	0.8	0
51	The effects of Mediterranean diet on memory and Alzheimer's disease biomarkers. Alzheimer's and Dementia, 2020, 16, e045349.	0.8	0
52	Performance comparison of automated white matter lesion segmentation algorithms in the DELCODE Study. Alzheimer's and Dementia, 2020, 16, e045367.	0.8	0
53	Use of Cerebrospinal Fluid Biomarkers of Alzheimerâ€™s Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany. Journal of Alzheimer's Disease, 2020, 78, 1137-1148.	2.6	5
54	Bupropion for the Treatment of Apathy in Alzheimer Disease. JAMA Network Open, 2020, 3, e206027.	5.9	18

#	Article	IF	Citations
55	Oligodendrocytes Provide Antioxidant Defense Function for Neurons by Secreting Ferritin Heavy Chain. Cell Metabolism, 2020, 32, 259-272.e10.	16.2	98
56	PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. Acta Neuropathologica, 2020, 139, 1025-1044.	7.7	40
57	Minor neuropsychological deficits in patients with subjective cognitive decline. Neurology, 2020, 95, e1134-e1143.	1.1	58
58	Association of domainâ€specific cognitive functions with regional pattern of atrophy and functional connectivity across the Alzheimerâ€™s disease spectrum: An analysis from the DELCODE cohort. Alzheimer's and Dementia, 2020, 16, e042992.	0.8	0
59	Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study. Alzheimer's Research and Therapy, 2019, 11, 66.	6.2	74
60	Choroid plexusâ€derived miRâ€204 regulates the number of quiescent neural stem cells in the adult brain. EMBO Journal, 2019, 38, e100481.	7.8	52
61	A combined miRNAâ€“piRNA signature to detect Alzheimerâ€™s disease. Translational Psychiatry, 2019, 9, 250.	4.8	74
62	The atrophy pattern in Alzheimer-related PPA is more widespread than that of the frontotemporal lobar degeneration associated variants. NeuroImage: Clinical, 2019, 24, 101994.	2.7	18
63	Memorability of photographs in subjective cognitive decline and mild cognitive impairment: Implications for cognitive assessment. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 610-618.	2.4	17
64	Multicenter Tract-Based Analysis of Microstructural Lesions within the Alzheimerâ€™s Disease Spectrum: Association with Amyloid Pathology and Diagnostic Usefulness. Journal of Alzheimer's Disease, 2019, 72, 455-465.	2.6	15
65	Higher CSF Tau Levels Are Related to Hippocampal Hyperactivity and Object Mnemonic Discrimination in Older Adults. Journal of Neuroscience, 2019, 39, 8788-8797.	3.6	64
66	Structural integrity in subjective cognitive decline, mild cognitive impairment and Alzheimerâ€™s disease based on multicenter diffusion tensor imaging. Journal of Neurology, 2019, 266, 2465-2474.	3.6	35
67	Unraveling corticobasal syndrome and alien limb syndrome with structural brain imaging. Cortex, 2019, 117, 33-40.	2.4	17
68	Translocator Protein Ligand Protects against Neurodegeneration in the MPTP Mouse Model of Parkinsonism. Journal of Neuroscience, 2019, 39, 3752-3769.	3.6	46
69	ICâ€Pâ€028: PATTERNS OF INCREASED AND DECREASED PRECUNEUS FUNCTIONAL CONNECTIVITY IN SCD DEPENDING ON AMYLOID STATUS. Alzheimer's and Dementia, 2019, 15, P35.	0.8	0
70	ICâ€Pâ€016: CORTICAL AMYLOID BURDEN CORRELATES WITH ATROPHY OF THE POSTERIOR PART OF THE NUCLEUS BASALIS MEYNERT IN AMYLOIDâ€POSITIVE SCD. Alzheimer's and Dementia, 2019, 15, P25.	0.8	0
71	Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 4-10.	1.9	96
72	Evaluation of the methoxy-X04 derivative BSC4090 for diagnosis of prodromal and early Alzheimerâ€™s disease from bioptic olfactory mucosa. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 973-984.	3.2	3

#	Article	IF	Citations
73	The applause sign in frontotemporal lobar degeneration and related conditions. Journal of Neurology, 2019, 266, 330-338.	3.6	15
74	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimerâ€™s disease. Brain, 2018, 141, 1186-1200.	7.6	83
75	Prediction and Early Detection of Alzheimerâ€™s Dementia: Professional Disclosure Practices and Ethical Attitudes. Journal of Alzheimer's Disease, 2018, 62, 145-155.	2.6	29
76	Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimerâ€™s disease (DELCODE). Alzheimer's Research and Therapy, 2018, 10, 15.	6.2	131
77	A language-based sum score for the course and therapeutic intervention in primary progressive aphasia. Alzheimer's Research and Therapy, 2018, 10, 41.	6.2	8
78	Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimerâ€™s Dementia in Individuals With Previous Depression. American Journal of Psychiatry, 2018, 175, 232-241.	7.2	133
79	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 239-247.	1.9	89
80	P1â€379: CORTICAL THINNING IN SUBJECTIVE COGNITIVE DECLINE WITH AND WITHOUT AD PATHOLOGY: DATA FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P443.	0.8	0
81	P3â€327: NEUROPSYCHIATRIC SYMPTOMS IN ATâ€RISK GROUPS FOR AD DEMENTIA AND THEIR RELATION TO AD BIOMARKERS: DATA FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1206.	0.8	0
82	P2â€434: EFFECTS OF AGE AND CSF MEASURES OF TAU ON MNEMONIC DISCRIMINATION OF OBJECTS AND SCENES IN MEDIAL TEMPORAL LOBE PATHWAYS. Alzheimer's and Dementia, 2018, 14, P879.	0.8	0
83	P2â€455: STRUCTURAL INTEGRITY IN SUBJECTIVE COGNITIVE DECLINE, MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P894.	0.8	0
84	ICâ€Pâ€084: EFFECTS OF AGE AND CSF MEASURES OF TAU ON MNEMONIC DISCRIMINATION OF OBJECTS AND SCENES IN MEDIAL TEMPORAL LOBE PATHWAYS. Alzheimer's and Dementia, 2018, 14, P72.	0.8	0
85	P1â€028: OCCUPATIONAL COGNITIVE REQUIREMENTS ARE AN IMPORTANT PROXY MEASURE OF COGNITIVE RESERVE: EVIDENCE FROM THE AGECODE AND DELCODE STUDIES. Alzheimer's and Dementia, 2018, 14, P276.	0.8	0
86	P3â€366: MULTICENTER RESTING STATE FUNCTIONAL CONNECTIVITY IN PRODROMAL AND DEMENTIA STAGES OF ALZHEIMER'S DISEASE: RESULTS FROM THE DZNE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1228.	0.8	0
87	ICâ€Pâ€155: STRUCTURAL INTEGRITY IN SUBJECTIVE COGNITIVE DECLINE, MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P131.	0.8	0
88	P3â€591: A GERMAN VERSION OF THE LIFETIME OF EXPERIENCES QUESTIONNAIRE (LEQ) TO MEASURE COGNITIVE RESERVE: VALIDATION RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1352.	0.8	8
89	F4â€07â€03: RELATIONSHIP BETWEEN LOCUS COERULEUS MRI CONTRAST, COGNITION AND CSF BIOMARKERS IN AGING AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1393.	0.8	0
90	ICâ€Pâ€163: MICROSTRUCTURAL CHANGES IN ALZHEIMER'S DISEASE, MILD COGNITIVE IMPAIRMENT, AND SUBJECTIVE COGNITIVE DECLINE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: A TBSS ANALYSIS OF DELCODE DATA. Alzheimer's and Dementia, 2018, 14, P137.	0.8	0

#	Article	IF	Citations
91	F1â€04â€02: ASSOCIATION BETWEEN NEURAL NOVELTY RESPONSES AND CSF BIOMARKERS OF ALZHEIMER'S DISEASE: ANATOMICAL SPECIFICITY AND DEPENDENCE ON ATROPHY. Alzheimer's and Dementia, 2018, 14, P206.	0.8	0
92	F4â€08â€04: SUBJECTIVE COGNITIVE DECLINE, AS MEASURED WITH A STRUCTURED INTERVIEW, IS RELATED TO AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P1396.	0.8	0
93	F1â€04â€03: EFFECTS OF AGE AND TAU MEASURED IN CSF ON MNEMONIC DISCRIMINATION OF OBJECTS AND SCENES IN MEDIAL TEMPORAL LOBE PATHWAYS. Alzheimer's and Dementia, 2018, 14, P207.	0.8	0
94	P4â€068: LEVELS OF THE ASTROCYTEâ€ÐERIVED PROTEINS GFAP AND S100B IN THE CEREBROSPINAL FLUID OF HEALTHY INDIVIDUALS AND ALZHEIMER'S DISEASE PATIENTS AT DIFFERENT DISEASE STAGES. Alzheimer's and Dementia, 2018, 14, P1458.	0.8	1
95	P2â€431: RELATIONSHIP BETWEEN LOCAL RESTING STATE ACTIVITY, Î²â€AMYLOID DEPOSITION AND MEMORY PERFORMANCE IN THE DZNE: LONGITUDINAL COGNITIVE IMPAIRMENT AND DEMENTIA STUDY (DELCODE). Alzheimer's and Dementia, 2018, 14, P877.	0.8	0
96	P2â€447: MICROSTRUCTURAL CHANGES IN ALZHEIMER'S DISEASE, MILD COGNITIVE IMPAIRMENT, AND SUBJECTIVE COGNITIVE DECLINE BASED ON MULTICENTER DIFFUSION TENSOR IMAGING: A TBSS ANALYSIS OF DELCODE DATA. Alzheimer's and Dementia, 2018, 14, P888.	0.8	0
97	CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 782-790.	2.4	26
98	Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology, 2018, 91, e1390-e1401.	1.1	85
99	Mitochondria, lysosomes, and dysfunction: their meaning in neurodegeneration. Journal of Neurochemistry, 2018, 147, 291-309.	3.9	84
100	A Modified Reading the Mind in the Eyes Test Predicts Behavioral Variant Frontotemporal Dementia Better Than Executive Function Tests. Frontiers in Aging Neuroscience, 2018, 10, 11.	3.4	34
101	Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients â€“ An Atlas-Based Volumetric MRI Study. Frontiers in Aging Neuroscience, 2018, 10, 45.	3.4	40
102	Multicenter Resting State Functional Connectivity in Prodromal and Dementia Stages of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 64, 801-813.	2.6	19
103	The diphenylpyrazole compound anle138b blocks Aβ2 channels and rescues disease phenotypes in a mouse model for amyloid pathology. EMBO Molecular Medicine, 2018, 10, 32-47.	6.9	63
104	The release and trans-synaptic transmission of Tau via exosomes. Molecular Neurodegeneration, 2017, 12, 5.	10.8	475
105	Predicting primary progressive aphasias with support vector machine approaches in structural MRI data. NeuroImage: Clinical, 2017, 14, 334-343.	2.7	42
106	Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurology, 2017, 88, 961-969.	1.1	73
107	Predicting behavioral variant frontotemporal dementia with pattern classification in multi-center structural MRI data. NeuroImage: Clinical, 2017, 14, 656-662.	2.7	64
108	Polyâ€<scp>GP</scp> in cerebrospinal fluid links C9orf72â€associated dipeptide repeat expression to the asymptomatic phase of <scp>ALS</scp>/<scp>FTD</scp>. EMBO Molecular Medicine, 2017, 9, 859-868.	6.9	90

#	Article	IF	Citations
109	Tau plasma levels in subjective cognitive decline: Results from the DELCODE study. Scientific Reports, 2017, 7, 9529.	3.3	27
110	[P2â€“074]: MODELING OF HIDDEN CAUSES FOR DYNAMIC CHANGES IN STRUCTURAL INTEGRITY AND COGNITION IN SUBJECTIVE COGNITIVE DECLINE: A DELCODE PROJECT. Alzheimer's and Dementia, 2017, 13, P634.	0.8	0
111	[ICâ€Pâ€080]: USEFULNESS AND STABILITY OF MULTICENTER DIFFUSION TENSOR IMAGING AS AN EARLY MARKER FOR SUBJECTIVE COGNITIVE DECLINE AND AMNESTIC MILD COGNITIVE IMPAIRMENT: FIRST RESULTS FROM THE PROSPECTIVE DZNE DELCODE STUDY. Alzheimer's and Dementia, 2017, 13, P66.	0.8	2
112	[P2â€“390]: LOCAL AND GLOBAL RESTING STATE ALTERATIONS IN DIFFERENT STAGES DURING THE DEVELOPMENT OF ALZHEIMER's DISEASE AS DEMONSTRATED IN THE DZNE DELCODE COHORT. Alzheimer's and Dementia, 2017, 13, P779.	0.8	1
113	[P3â€“393]: ROBUST AUTOMATED DETECTION OF SUBJECTIVE COGNITIVE DECLINE AND PRODROMAL ALZHEIMER's DISEASE BASED ON MULTICENTER RESTINGâ€STATE FUNCTIONAL CONNECTIVITY: RESULTS FROM THE DZNE DELCODE STUDY. Alzheimer's and Dementia, 2017, 13, P1112.	0.8	0
114	[P3â€“437]: LATENTâ€FACTOR STRUCTURE OF THE DELCODE STUDY NEUROPSYCHOLOGICAL TEST BATTERY. Alzheimer's and Dementia, 2017, 13, P1136.	0.8	2
115	[P1â€“122]: WHAT IS MEMORABLE IS CONSERVED ACROSS HEALTHY AGING, EARLY ALZHEIMER's DISEASE, AND NEURAL NETWORKS. Alzheimer's and Dementia, 2017, 13, P287.	0.8	2
116	[P4â€“248]: QUALITY ASSURANCE IN DELCODE: A MULTIâ€CENTER NEUROIMAGING STUDY. Alzheimer's and Dementia, 2017, 13, P1372.	0.8	0
117	[P4â€“532]: OBJECT AND SCENE MEMORY ARE DIFFERENTIALLY ASSOCIATED WITH CSF MARKERS OF ALZHEIMER's DISEASE AND MRI VOLUMETRY. Alzheimer's and Dementia, 2017, 13, P1553.	0.8	0
118	P1-010: Face Name Associative Recognition is Associated with Alzheimerâ€™s Disease Biomarkers in Patients with Subjective Cognitive Decline. , 2016, 12, P402-P403.		0
119	Catching filopodia: Exosomes surf on fast highways to enter cells. Journal of Cell Biology, 2016, 213, 143-145.	5.2	9
120	Atrophy and structural covariance of the cholinergic basal forebrain in primary progressive aphasia. Cortex, 2016, 83, 124-135.	2.4	21
121	The brain as immunoprecipitator of serum autoantibodies against Nâ€Methylâ€Dâ€aspartate receptor subunit NR1. Annals of Neurology, 2016, 79, 144-151.	5.3	75
122	P2â€335: Prevalence of Preclinical Alzheimer's Disease in Patients with Subjective Cognitive Decline: Comparison of Three European Memory Clinic Samples. Alzheimer's and Dementia, 2016, 12, P770.	0.8	0
123	Induction of Î±-synuclein aggregate formation by CSF exosomes from patients with Parkinsonâ€™s disease and dementia with Lewy bodies. Brain, 2016, 139, 481-494.	7.6	349
124	Super-Resolution Microscopy of Cerebrospinal Fluid Biomarkers as a Tool forÂAlzheimerâ€™s Disease Diagnostics. Journal of Alzheimer's Disease, 2015, 46, 1007-1020.	2.6	12
125	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Frontiers in Neurology, 2015, 6, 216.	2.4	36
126	Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type. Neurobiology of Aging, 2015, 36, 601-607.	3.1	125

#	Article	IF	Citations
127	Neuron-to-neuron Î±-synuclein propagation in vivo is independent of neuronal injury. Acta Neuropathologica Communications, 2015, 3, 13.	5.2	75
128	Extracellular vesicle sorting of Î±-Synuclein is regulated by sumoylation. Acta Neuropathologica, 2015, 129, 695-713.	7.7	136
129	In vivo markers of Parkinsonâ€™s disease and dementia with Lewy bodies: current value of the 5G4 Î±-synuclein antibody. Acta Neuropathologica, 2014, 128, 893-5.	7.7	8
130	Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 351-356.	1.7	131
131	Turn Plasticity Distinguishes Different Modes of Amyloid-Î² Aggregation. Journal of the American Chemical Society, 2014, 136, 4913-4919.	13.7	39
132	Exosomes: vesicular carriers for intercellular communication in neurodegenerative disorders. Cell and Tissue Research, 2013, 352, 33-47.	2.9	253
133	Epigenetic dysregulation in schizophrenia: molecular and clinical aspects of histone deacetylase inhibitors. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 273-284.	3.2	44
134	Myelin Membrane Assembly Is Driven by a Phase Transition of Myelin Basic Proteins Into a Cohesive Protein Meshwork. PLoS Biology, 2013, 11, e1001577.	5.6	148
135	Neurotransmitter-Triggered Transfer of Exosomes Mediates Oligodendrocyteâ€“Neuron Communication. PLoS Biology, 2013, 11, e1001604.	5.6	663
136	Differential Expression of Exosomal microRNAs in Prefrontal Cortices of Schizophrenia and Bipolar Disorder Patients. PLoS ONE, 2013, 8, e48814.	2.5	205
137	Antioxidative strategies in cognitive impairment: a novel connection between biliverdinâ€reductase and statins. Journal of Neurochemistry, 2012, 120, 1-3.	3.9	3
138	Exosome Secretion Ameliorates Lysosomal Storage of Cholesterol in Niemann-Pick Type C Disease. Journal of Biological Chemistry, 2010, 285, 26279-26288.	3.4	199
139	Upâ€regulation of the Î±â€secretase ADAM10 by retinoic acid receptors and acitretin. FASEB Journal, 2009, 23, 1643-1654.	0.5	195
140	A Novel Mutation of the Arylsulfatase A Gene in Late-Onset Metachromatic Leukodystrophy. Journal of Clinical Psychiatry, 2009, 70, 1724-1725.	2.2	4
141	Tau-Based Treatment Strategies in Neurodegenerative Diseases. Neurotherapeutics, 2008, 5, 443-457.	4.4	128
142	Efficient Inhibition of the Alzheimer's Disease Î²-Secretase by Membrane Targeting. Science, 2008, 320, 520-523.	12.6	254
143	Flotillin-Dependent Clustering of the Amyloid Precursor Protein Regulates Its Endocytosis and Amyloidogenic Processing in Neurons. Journal of Neuroscience, 2008, 28, 2874-2882.	3.6	180
144	Myelin basic protein-dependent plasma membrane reorganization in the formation of myelin. EMBO Journal, 2006, 25, 5037-5048.	7.8	99

#	Article	IF	Citations
145	Cholesterol depletion reduces aggregation of amyloid-beta peptide in hippocampal neurons. Neurobiology of Disease, 2006, 23, 573-577.	4.4	80
146	Neuron to glia signaling triggers myelin membrane exocytosis from endosomal storage sites. Journal of Cell Biology, 2006, 172, 937-948.	5.2	151
147	Palmitoylation is a sorting determinant for transport to the myelin membrane. Journal of Cell Science, 2005, 118, 2415-2423.	2.0	46
148	Hyperphosphorylation and Aggregation of Tau in Experimental Autoimmune Encephalomyelitis. Journal of Biological Chemistry, 2004, 279, 55833-55839.	3.4	55
149	Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathologica, 2002, 103, 26-35.	7.7	849
150	Microtubule-Affinity Regulating Kinase (MARK) Is Tightly Associated with Neurofibrillary Tangles in Alzheimer Brain: A Fluorescence Resonance Energy Transfer Study. Journal of Neuropathology and Experimental Neurology, 2000, 59, 966-971.	1.7	82
151	Rapid Assembly of Alzheimer-like Paired Helical Filaments from Microtubule-Associated Protein Tau Monitored by Fluorescence in Solution. Biochemistry, 1998, 37, 10223-10230.	2.5	378
152	Feasibility of Digital Memory Assessments in an Unsupervised and Remote Study Setting. Frontiers in Digital Health, 0, 4, .	2.8	12